• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    powder inhaler. the present invention relates to an inhaler for inhaling powdered capsule medicaments, comprising: - a bottom part (6), - a plate (3) received on the part of the funfo (6), and an assembly (18) inserted on the bottom part (6), - a nozzle (2) that can be engaged with the bottom part (6) on the plate (3), - a cover (1) that covers the nozzle (2) in a closed position and engages by means of a closing element (14), in which the bottom part (6) and the cover (1) are rotationally connected to each other by an axis (4), and - an actuating member (7, 10), which can be set in motion from a resting position and in the process cooperates with at least one needle (8, 11) which can pierce the assembly (18), the needle being located in a needle retainer of the inner actuating member (10 ). a replaceable tube (22) can be inserted into the assembly (18) as a discharge channel, the tube comprising a capsule chamber (21) with the capsule.
    公开号:BR112012007303B1
    申请号:R112012007303-6
    申请日:2010-09-30
    公开日:2020-12-15
    发明作者:Markus Kaemper；Joern-Eric SCHULZ
    申请人:Boehringer Ingelheim International Gmbh；
    IPC主号:
    专利说明:

    [001] The present invention relates to an inhaler.
    [002] An inhaler known from the prior art is described, for example, in EP 0703800 B1 or EP 0911047 A1. The inhaler known from the aforementioned publications has a dish-shaped bottom and a corresponding dish-like lid that can be folded open for use by means of a hinge provided in the edge region. Between the bottom and the cover, on the hinge, there is also a nozzle that can be folded out and a plate located below it with a capsule retainer located below. After the individual sets have been opened separately, the patient can insert a drug-filled capsule into the capsule retainer, pivot the plate with the capsule retainer and the nozzle back to the bottom and pierce the capsule through an acting member with spring that protrudes laterally from the bottom. The medication is then taken to the patient's airway being treated by suction in the mouthpiece.
    [003] The aim of the invention is to improve the inhaler known from the prior art even further in terms of its handling.
    [004] This goal is achieved according to the invention with an inhaler and a replaceable tube for an inhaler according to the characteristics of the invention.
    [005] The embodiments represent the advantageous embodiments of the invention.
    [006] The inhaler for inhaling powdered medicine capsules comprises: - a lower part, - a plate accommodated at the bottom, and a retainer inserted in the lower part, - a mouthpiece that can be attached to the lower part of the plate, - a cover that covers the nozzle in a closed position and engages by means of a closing element, the lower part and the cover being rotatorily connected to each other by a spindle, and - an actuating member that can be moved from a position of resting and set in motion and at the same time cooperates with at least one pin that can be inserted into the retainer and is located in a pin retainer on the inner actuating member.
    [007] In the retainer, a replaceable tube, as an expulsion channel, can be inserted that comprises a capsule chamber with the capsule.
    [008] As a result of these measures, the operability of the inhaler is improved to inhale powdered medications from capsules, as before using the capsule inhaler together with the replaceable tube in the form of a disposable part that forms an expulsion channel for the powder is inserted directly into the retainer disposed in the inhaler.
    [009] This results in easier handling for the user, since patients with reduced or weak hand strength find it easier, thanks to the size, to insert the replaceable tube with the capsule contained in it, than to place a capsule separately in a capsule chamber, as taught in the prior art. In addition, after nebulization or inhalation, all components of the inhaler that are notoriously affected by dust are replaced so that the next time the inhaler is used a new replaceable tube, that is, an unused expulsion channel, is provided.
    [0010] The new replaceable tube also has an advantage with drug formulations that have a tendency to form deposits in the powder expulsion path, since naturally there is no deposit in an unused expulsion channel caused by previous use of the inhaler.
    [0011] The replaceable tubes, each containing at least one capsule, can be taken by the patient from any packaging that is available according to the current state of the art (for example, a blister pack, cardboard or containers with or without individual bags or bags). Depending on the physical properties of the medicine that is to be inhaled, the skilled person will select the appropriate packaging for the replaceable tube.
    [0012] The inhaler corresponds in its function, particularly in terms of inhalation, that is, the flow path of the powdered medicine, to the inhaler described in WO 2009/013218, which is hereby incorporated by reference. This applies particularly to the drilling process.
    [0013] The inhaler essentially consists of an upper part formed by the mouthpiece which is protected by a cover, and an inferior part of two parts in the form of a cup.
    [0014] In the inner region of the cover is a cross piece, as known from WO 2009/013218. By means of this crosspiece, in the inhaler according to the invention, it is not the mouthpiece, but the replaceable tube that is pressed into the final position when the cover is closed. In addition, the cover has an account that runs in and out and is not externally visible. This account serves to close the cover on the actuating member that is located at the bottom of the inhaler.
    [0015] To allow the cover to be separated from the bottom, the actuating member has on its upper side a recess that is inclined so that it forms a sliding surface for the closing element, in the form of an inclined plane, and when actuated and consequently, when the actuating member is advanced, it releases the bottom cover. This function is only possible when the replaceable tube is fully inserted. The recess in the active member can be of various sizes. The minimum size must be such that it is possible to release the cover from the bottom in the manner of a pocket watch. Its maximum size depends on the top of the actuating member. The current opening movement of the cover can then be performed by the patient, acting on the cover, and folding the cover completely open. In addition to the release of the coupling by the actuating member, by an appropriate choice of size for the recess in the actuating member and the bill in the cover, the retention force can also be overcome manually by the patient pulling the cover manually over the capture without acting any another element.
    [0016] In one embodiment, to assist the opening movement, a spring element, for example, can be arranged between the cover and / or the bottom, which is particularly in the form of two plates, so that when the dimensions suitable, the cover opens under pressure. Alternatively, it is also obviously possible to have an inhaler modality without a spring element between the cover and the bottom. The cover can then be opened under a spring effect by an appropriate choice of bead.
    [0017] The acting member is of greater importance, particularly at the beginning of an asthma attack. The effective arrangement of the active limb combined with a reduced application of force by the patient makes using the inhaler considerably easier. This is particularly true for patients suffering from arthritis or similar illnesses or having reduced mobility of the fingers for some other reason.
    [0018] The actuating member consists of two components, and comprises an internal part and an external part. The inner part has two parallel guide arms. The guide arms protrude towards the bottom and together with the corresponding inserts, for example, with the guide nets or gloves arranged on the outside of the retainer or on the inside of the lower halves, they serve to guide the actuating member during movement from the resting position to the respective operating positions and back to the resting position. Preferably, the actuating member comprises fastening elements, for example, in the form of snap-on hooks that ensure both secure assembly and robust operation of the device as a whole. The pivotally mounted outer part of the actuating member, when actuated, compresses by means of a rounded contact surface on the inner part which then moves in a linear manner to adhere the pins in the capsule. The contact surface can be formed both internally and externally, but preferably only internally.
    [0019] The actuating member is connected to the bottom or both halves of the bottom. This can be achieved by means of snap-on hooks, hitch hooks or similar technical solutions. In addition, the actuating member can be movably mounted between the bottom halves in free space.
    [0020] Preferably, the actuating member is movably mounted on the bottom or on the retainer. It is also possible to mount it on the nozzle. The bottom or bottom halves preferably comprise (m) laterally mounted guide nets which are, however, also located on the plate and can be supported on the bottom or side plates of the bottom.
    [0021] In a favorable mode, the actuating member has a spring. The restoring force present even in the resting position ensures that after the actuating member has been used it returns to the resting position and in this way the inhalation process can be started or continued. The guide arms may have end stops at their remote end of the main body, these stops supporting the retainer or guide sleeves in the resting position. This creates a reproducible spring tension in the actuating member that ensures that all necessary components are precisely positioned in the operating position. The guide arms can be of any desired shape and arrangement (for example, converging or diverging). In addition, it is possible to have one or more of two guide arms. The construction can be based on a round shape in the cross section or any desired profile.
    [0022] Altogether, the actuating member has at least one limit region that can be provided when desired in the internal or external compression part. In a preferred embodiment, the main body of the actuating member can have at least one grooved surface on the outside. This grooved surface can be at the top, bottom or sides. Preferably, the grooved surface will be on at least one handle on the actuating member. The grooved surface acts both as a design element and to ensure optimum grip during actuation. This is located in the main body of the actuating member outside the region of inhalation and, therefore, does not come into contact with the region of the patient's mouth. In addition, the grooved surface can be smaller in area than the total surface area of the actuating member and still offers a guarantee of safe and quick use of the inhaler. In addition, of course, it is possible to provide the bottom and / or the cover with grooved surfaces also to further improve the handling of the inhaler.
    [0023] For a better understanding of the invention, it will now be described in more detail with reference to the drawings to follow, in which:
    [0024] figure 1 shows an exploded view of an inhaler according to the prior art,
    [0025] Figure 2 shows an exploded view of an inhaler according to the invention, and
    [0026] Figure 3 shows a sectional view of the inhaler according to Figure 2.
    [0027] Figure 1 shows a prior art inhaler. The essential components of the inhaler are a lower part 6 that accommodates a plate 3 and is covered by this plate, a mouthpiece 2 that can be attached to plate 3 by means of retaining ears of a screen housing 12 and a cover 1 that is designed to be complementary to the bottom 6. The plate 3, the bottom 6, the nozzle 2 and the cover 1 are mounted on a spindle 4.
    [0028] In the closed state of the inhaler, a closing element 14 in the cover 1 engages an external actuating member 7 and is frictionally retained therein. It is also possible to provide a locking bezel by means of bead-like formations in the closing element 14. For the closing element 14 to act on the cover 1, the external actuating member 7 comprises a recess to which the closing element 14 is lowered during the closing operation.
    [0029] The actuating member consists of the external actuating member 7 and an internal actuating member 10. In order to open the cover 1, first the external actuating member 7 can be moved or pressed towards the inhaler. The closing element 14 in the cover 1, however, establishes contact with the recess which, as the closing element 14 advances further, acts as a sliding surface and ensures that the cover 1 is released. Similarly, the cover 1 can be raised manually by the user without pressing on the actuating member 7 and thereby the inhaler can be opened.
    [0030] The recess 16 connects the external and internal actuating members 7, 10 by means of a suspension that can take the form of a snap hook, pin or other suspension means, for example. The recess 16 can be round, oval or asymmetrical in shape. The recess 16 can be arranged in a horizontal or vertical position or in any position. Preferably, the recess 16 is a so-called oblong orifice, i.e., an elongated oval that provides optimum orientation of the pins in the axial direction to ensure accurate drilling of the capsule.
    [0031] The bottom 6 is cup-shaped and completely accommodates a capsule retainer 5 disposed on the underside of the plate 3. To be able to place a drug filled capsule (not shown) inside the capsule retainer 5, nozzle 2 must also be removed. In the mode according to figure 1, this is done by activating the opening aid 2 'which is provided in the nozzle 2.
    [0032] In this open position of the cover 1 and the nozzle 2, the capsule can be placed in the capsule retainer 5 through an opening in the plate 3. The nozzle 2 is then pivoted back again and engaging the retaining ears of the housing. screen 12 which is frictionally connected to the nozzle on plate 3 is closed again. The screen housing 12 contains the screen mesh 13 at its center. Screen mesh 13 consists of standard commercial materials such as metal or plastics, for example. In the latter case, the web can be produced by extrusion molding. To release the active substance, the external actuating member 7 is operated. It is designed so that the pin retainer is above the point of application of the force and below the suspension for the operational switch. In the inner actuating member 10 there is at least one pin, but preferably two, perpendicularly offset and parallel pins 8, 11 that move continuously when the actuating member 7,10 is pushed towards the capsule (not shown) and pierces this capsule . The drilling process can be observed through a 6 'inspection window.
    [0033] In the capsule retainer 5 there are two tubular guides of pin 20 that are axially aligned according to the direction of movement of the pins 8, 11. In this way, the provision is made for precisely targeted application of the pins 8, 11 for the capsule (not shown), on the one hand, and for additional guide of the actuating member 7, 10, on the other hand. However, the essential guidance is provided by means of two 20 'laterally arranged guide sleeves. Guide arms 15, in collaboration with guide gloves 20 ’, have the task of retaining the actuating member 7, 10 under a driving force. For this purpose, the guide arms are provided with end stops 15 at their remote ends of the main body, these end stops touching the guide sleeves of the capsule retainer 5 in the resting position of the actuating member 7, 10. The are located outside the capsule retainer 5. Between the guide arms 15, a helical spring 9 is arranged that extends parallel to the pins 8, 11 in its axial direction, the helical spring 9 being paired to the length of the arms -guide 15 so that the actuating member 7, 10 is still propelled in the rest position.
    [0034] The individual assemblies comprising the bottom 6, the plate 3, the nozzle 2 and cover 1 are connected to each other by means of hinge recesses and a spindle 4 and are all pivotable with respect to each other around this spindle 4 .
    [0035] In the inhaler shown in the figures. 2 and 3, in contrast to the inhaler described above, the lower part 6 is made in two parts and comprises the plate 3 as an integral component. At the bottom 6 side retaining networks 17 are provided, each having a recess 42, for a retainer 18 and an opening 19 at the base, an opening 44 in the plate 3 [sic].
    [0036] The retainer 18 is provided with two tubular guides of pin 20 and is retained by the retaining net 17 arranged in the lower part 6 with the recess 42 and the opening 44 in the two-part plate 3.
    [0037] Capsule 21 'with the medicine to be inhaled is located in a capsule chamber 21 in a so-called replaceable tube 22 which is pushed into the inhaler through nozzle 2 and retainer 18. The replaceable tube 22 it essentially consists of a plastic tube which is filled with the capsule underneath and is closed off with a plug 23 preferably also made of a plastic, the plug 23 being provided with an axial hole 40 to form a flow channel. By providing an injection of the transfer member 41 molded into the replaceable tube 22, the capsule is prevented from falling in the upward direction and the space it requires to vibrate during inhalation, i.e., the length of the capsule chamber, is determined. Preferably, plug 23 is a separate component that cannot be removed once fitted to replaceable tube 22. On its underside, plug 23 comprises slopes or functional surfaces 32 that can be used to eject replaceable tube 22. The upper part the replaceable tube 22 forms the entire airway through which the nebulized powder formulation travels before being inspired by the patient using the inhaler.
    Alternatively, the plug 23 can also be fixedly molded on the replaceable tube 22 and the cross member 41 can also be provided as a separately multiple component for inserting the capsule. Another alternative could be an injection of replaceable tube 22 completely molded with the plug 23 and the cross member 41 which comprises a lockable side opening for the introduction of the capsule. It is also possible to construct the replaceable tube 22 in several parts.
    [0039] The airway of the replaceable tube 22 is adapted for inhalation of the active substances that are to be inhaled, so that compared to the prior art inhaler the internal diameter of the airway may be larger or smaller. The cross member 41 forms both the required height of the capsule chamber 21 within the replaceable tube 22 to allow the capsule to vibrate to achieve the required supply of powder, as well as having an air resistance that is adapted to the active substance formulation.
    [0040] After being pushed into the inhaler, the ends of the replaceable tube 22 flow with the nozzle 2 into its upper surface in the position of use, so that the user would not be able to detect a step. In this position, the two pin tube guides 20 of the retainer 18 are in alignment with the circumferential openings 24 for the pins 8, 11 in the replaceable tube 22. It is also possible for the part of the nozzle 2 even in the outer region to count as the tube replaceable 22, so that the junction of the replaceable tube 22 with the nozzle 2 can be at any desired point. This ensures that the replaceable tube 22 is inserted correctly, a mechanism is integrated into the inhaler that prevents the actuating member 7, 10 from being actuated before the replaceable tube 22 assumes its correct final position in order to pierce the capsule with pins 8 , 11. The actuating member 7, 10 can be locked so that no actuation is possible, that is, the cover 1 cannot be opened, and preferably the closing element is designed so that the cover 1 can be opened if no replaceable tube 22 was inserted. Preferably, the position of the replaceable tube 22 can be easily recognizable from a colored marking in the upper region of the replaceable tube 22. When the replaceable tube 22 is inserted correctly in the final position, that marking disappears with the nozzle 2 and is no longer visible. In addition, the cover 1 which covers the nozzle 2 in a closed position has, in its interior, a neck 45 which in the closed state of the cover, compresses on the replaceable tube 22 inserted in it and in the nozzle.
    [0041] Thus, the replaceable tube 22 is correctly positioned in the inhaler, the replaceable tube 22 comprises, in the region of its upper surface 25 associated with the mouthpiece 2, an insertion cone 26 that is in a correspondingly shaped opening 27 in the nozzle 2 in the axial position of use of the replaceable tube 22. To also ensure the radial alignment of the replaceable tube 22, the replaceable tube 22 is provided, in the region of its upper surface 25 associated with the nozzle 2, with a radial projection ear 28 that has a corresponding associated groove 29 in the opening 27 of the mouthpiece 2. The combination of ear 28 and groove 29 can also be used for active substance coding, if necessary, in suitable dimensions or geometries, so that an inhaler can only be even operated with an active substance. Another idea that was considered is that the replaceable tubes 22 should have different outside diameters so that the upper end 25 could not be inserted first.
    [0042] In the lower region of the replaceable tube 22 there is an annular groove 30, in this case circumferential in shape that enters into a connection with the plug 23. In addition, a radial action hook 43 is releasably provided to retain the replaceable tube 22 releasably in the inhaler by engaging. The depression 31 required for this can be circumferential, while alternatively the function can be performed by means of individual notches, nets or the like. It is also possible to provide at least one depression for engaging the replaceable tube 22 on the retainer 18 and an engaging hook on the replaceable tube 22.
    [0043] In another embodiment of the inhaler, the openings 24 for pins 8, 11 in the replaceable tube 22 can be closed by means of a counterpart membrane. The membrane can be produced directly by injection molding or produced by special methods using the same plastic component or a different one like the replaceable tube 22. The membrane cleans the dust that sticks to pins 8, 11 after drilling the capsule, as pins 8, 11 slide out of the capsule chamber 21, so pins 8, 11 are clean for the next use. This allows pins 8, 11 to be used many times to pierce the capsules containing the powder formulations.
    [0044] The chamber wall can be both a wall region of the capsule chamber 21, that is, of the replaceable tube 22, and a membrane in the region of the pin guide 20. In principle, the same membrane can certainly be used many times times as even after removing the pin it is sufficiently sealed to the remote side of the capsule and still remains impermeable even after it has been punctured several times. The principle can be transferred to all common pin shapes, both hollow and solid pins. For the membrane it is possible to use identical and different materials or combinations of materials and geometries, such as, for example, its thickness, to adjust the flexibility (solutions in a material with variations in the thickness of the layer are also possible), and it is possible to use any type of plastic such as hard or soft at room temperature eg TPEs, thermoplastics, rubbers and also materials consisting of other (inorganic) groups such as thin metal films, etc.
    [0045] When a capsule with a membrane in front of it is punctured, the membrane swells towards the end of the capsule as soon as it is punctured before the pin actually passes through; the membrane can be the chamber wall or can be directly connected to the chamber wall - either by conventional injection molding techniques or by 2-component injection molding or by a set of two or more parts. The fixation of the membrane can be achieved in any desired way: molded or extruded, cut, inserted, glued with additional material or, for example, by the self-adhesive effects of the membrane material, etc. Alternatively, cleaning of the sticky powder can also be carried out in a tight fit or flexible sleeve through which the pin 8, 11 is passed.
    [0046] As the replaceable tube 22 is inserted into the inhaler it first movably engages in an inserted intermediate position. As it is further inserted, a slightly increased resistance has to be overcome so that the replaceable tube 22 reaches its position of insertion. use liberally engaged. The resistance is caused by the fact that the coupling hook 43 acting on the replaceable tube 22 is molded on the retainer 18.
    [0047] Lockable under the cap 23 is a latch hook 33 located on slope 32 on one side or all around it. The coupling hook 33 is integrated in an intermediate ring 34 and is movably attached to the lower part 6 by means of a compression spring 35 and a retainer ring 36. The intermediate ring 34 has a coaxial actuator button 37 that passes through the retainer ring 36 and opening 19 at the bottom 6 for actuation by a user to release the engagement.
    [0048] Once the replaceable tube 22 with the capsule has been pushed into the inhaler (figure 3), nebulization occurs as in the previous inhaler. By means of the actuating member 7, 10 which can be operated with one or more fingers simultaneously, the capsule is pierced, through the corresponding openings 24 in the replaceable tube 22, through two pins 8, 11 on the top and bottom. The replaceable tube 22 is installed in a position oriented on the inhaler so that pins 8, 11 can actually penetrate the corresponding openings 24 on the replaceable tube 22. The helical spring 9 on the actuating member 7, 10 ensures that pins 8, 11 are automatically retracted from the capsule as soon as the actuating member 7, 10 is released. Inhalation occurs according to the principle tried and tested by the vibration of the capsule at the breath entrance by the patient as the latter sucks in the mouthpiece 2.
    [0049] After inhalation, the replaceable tube 22 with the now empty capsule in the capsule chamber 21 is released by pressing the actuator button 37, which in this mode is assisted with a spring, at the base of the inhaler, that is, on the opposite side of the nozzle 2. This actuator button 37 is lockable connected to the cap 23 by means of its integrated hook 33.
    [0050] By means of the spring drive of the intermediate ring 34, the clamping engagement of the replaceable tube 22 can be released, as the engagement hook 43 moves out of the groove with the associated recess 31, and the tube replaceable 22 is pushed upwards out of the inhaler. Depending on the design, solutions are possible in which the release of the replaceable tube 22 is carried out without the help of a spring, purely by the use of a slide. What is important is that a retention function for the replaceable tube 22 in the intermediate position is integrated into it, which has to be deliberately released, for example, using a key or button, before the replaceable tube 22 can be removed manually from the inhaler by pulling it that of the coupling hook 43. Mechanisms without spring or mechanisms that only partially eject the replaceable tube 22 are also possible. Another possibility here is to implement a secondary retention threshold in the intermediate position that holds the replaceable tube 22 after it has been ejected into a position protruding from the nozzle 2 from what can then be removed manually.
    [0051] If the replaceable tube 22 has just been ejected or a new replaceable tube 22 has not been pushed right as far as the end ends, a radial bar 39 molded in the intermediate ring 34 under the bottom 6 comes into effect. As a result of the action of the compression spring 35 on the inside, the bar 39 comes into contact with the external actuating member 7 so that its operation is prevented. The bar 39 blocks the external actuating member 7 with its ex-tremor free if no replaceable tube 22 is present or if the replaceable tube 22 is not in the engaged position of use. In this position, pins 8, 11 cannot move inward, that is, they cannot be damaged by a replaceable tube 22 that has not been inserted completely.
    [0052] This ensures that the pins 8, 11 always penetrate the openings 24 in the replaceable tube 22 that has been inserted in the required orientation and, for example, do not block the insertion opening for the replaceable tube 22 and / or become damaged. As the replaceable tube 22 is pushed into its engaged position of use, the intermediate ring 34 is pushed down on its inclined net pointing upwards 38 and the action of the cap 23 on the coupling hook 33 opposes the spring force of compression 35, so that the bar 39 is changed from the central path of the external actuating member 7. At the same time, the actuator button 37 returns to the ejection readiness, that is, it assumes an ideally flow position with the lower part 6 and can be reached by the user of the inhaler.
    [0053] The pins 8, 11 used can be any pins 8, 11 known to the skilled person and combinations thereof. They can be solid or hollow pins. Preferably, solid pins are used. The upper pin, in particular, (from the front to the mouthpiece) can be a triangular pin sharpened on three sides. The bottom pin can be a standard pin with a standard sharp edge, as specified for example in the German DIN standard.
    [0054] Alternatively, the upper pin 11 can be a standard pin with a standard sharp edge and the lower pin 8 can be a triangular pin sharpened on three sides. As a second alternative it is possible to use two triangular pins sharpened on three sides or two standard pins with a standard sharp edge.
    [0055] The capsules used can be any capsule known to man skilled in use in powder inhalers (for example, (hard) gelatin, plastic or metal capsules). In particular, a plastic capsule can be used in the inhaler according to the invention, as disclosed in WO 00/07572, EP 1 100 474.
    [0056] The inhaler may have an inspection window. However, this is not essential for its intended function.
    [0057] Similarly, all parts of the inhaler can be modified by methods known to the skilled person and procedures that are possible in plastics technology. Possible modifications include, for example, reinforcements or variations in wall thickness. However, these possibilities are not strictly necessary for the operation of the inhaler.
    [0058] The inhaler can also be coated inside and / or outside by methods known to the person skilled.
    [0059] All types of powdered medications that can be reasonably administered by inhalation for therapeutic purposes can be considered for inhalation.
    [0060] The compounds listed below can be used in the device according to the invention by itself or in combination. In the compounds mentioned below, W is a pharmacologically active substance and is selected (for example) from betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, H1-antihistamines, PAF antagonists and PI3 kinase inhibitors. In addition, double or triple W combinations can be combined and used in the device according to the invention. Combinations of W could be, for example: - W denotes a betamimetic, combined with an anticholinergic, corticosteroid, PDE4 inhibitor, EGFR inhibitor or LTD4 antagonist, - W denotes an anticholinergic, combined with a beta-mimetic, corticosteroid , PDE4 inhibitor, EGFR inhibitor or LTD4 antagonist, - W denotes a corticosteroid, combined with a PDE4 inhibitor, EGFR inhibitor or LTD4 antagonist, - W denotes a PDE4 inhibitor, combined with an EGFR inhibitor or antagonist LTD4, - W denotes an EGFR inhibitor, combined with a LTD4 antagonist.
    [0061] The compounds used as betamimetics are preferably compounds selected from albuterol, arformoterol, bamboo-terol, bitolterol, broxaterol, carbuterol, clenbuterol, phenoterol, formoterol, hexoprenaline, ibuterol, isoetarin, isoprenaline, levosalbutamol, mabutol, metaproterenol, orciprenaline, pyrbuterol, procaterol, reproterol, rimiterol, ritodrine, salmefamol, salmeterol, soterenol, sulfterol, terbutaline, thiaramide, tolubuterol, zinterol, CHF-1035, HOKU- 81, KUL-1248 and
    [0062] 3- (4- {6- [2-hydroxy-2- (4-hydroxy-3-hydroxymethyl-phenyl) -ethylamino] -hexyloxy} -butyl) -benzyl-sulfonamide
    [0063] 5- [2- (5,6-diethyl-indan-2-ylamino) -1-hydroxy-ethyl] -8-hydroxy-1H-quinolin-2-one
    [0064] 4-hydroxy-7- [2 - {[2 - {[3- (2-phenylethoxy) propyl] sulfonyl} ethyl] - amino} ethyl] -2 (3H) -benzothiazolone
    [0065] 1- (2-fluoro-4-hydroxyphenyl) -2- [4- (1-benzimidazolyl) -2-methyl-2-butylamino] ethanol
    [0066] 1- [3- (4-methoxybenzyl-amino) -4-hydroxyphenyl] -2- [4- (1-benzimidazolyl) -2-methyl-2-butylamino] ethanol
    [0067] 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- [3- (4-N, N-dimethylaminophenyl) -2-methyl-2- propylamino] ethanol
    [0068] 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- [3- (4-methoxyphenyl) -2-methyl-2-propylamino] ethanol
    [0069] 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- [3- (4-n-butyloxyphenyl) -2-methyl-2-propylamino] ethanol
    [0070] 1- [2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl] -2- {4- [3- (4-methoxyphenyl) -1,2,4-triazole -3-yl] -2-methyl-2-butylamino} ethanol
    [0071] 5-hydroxy-8- (1-hydroxy-2-isopropylaminobutyl) -2H-1,4-benzoxazin-3- (4H) -one
    [0072] 1- (4-amino-3-chloro-5-trifluoromethylphenyl) -2-tert-butylamino) ethanol
    [0073] 6-hydroxy-8- {1-hydroxy-2- [2- (4-methoxy-phenyl) -1,1-dimethyl-ethylamino] -ethyl} -4H-benzo [1,4] oxazin-3 -one
    [0074] 6-hydroxy-8- {1-hydroxy-2- [2- (4-phenoxy-ethyl acetate) -1,1-dimethyl-ethylamino] -ethyl} -4H-benzo [1,4] oxazin -3-one
    [0075] 6-hydroxy-8- {1-hydroxy-2- [2- (4-phenoxy-acetic acid) -1,1-dimethyl-ethylamino] -ethyl} -4H-benzo [1,4] oxazin- 3-one
    [0076] 8- {2- [1,1-dimethyl-2- (2,4,6-trimethylphenyl) -ethylamino] -1-hydroxy-ethyl} -6-hydroxy-4H-benzo [1,4] oxazin -3-one
    [0077] 6-hydroxy-8- {1-hydroxy-2- [2- (4-hydroxy-phenyl) -1,1-dimethyl-ethylamino] -ethyl} -4H-benzo [1,4] oxazin-3 -one
    [0078] 6-hydroxy-8- {1-hydroxy-2- [2- (4-isopropyl-phenyl) -1.1dimethyl-ethylamino] -ethyl} -4H-benzo [1,4] oxazin-3-one
    [0079] 8- {2- [2- (4-ethyl-phenyl) -1,1-dimethyl-ethylamino] -1-hydroxy-ethyl} -6-hydroxy-4H-benzo [1,4] oxazin-3 -one
    [0080] 8- {2- [2- (4-ethoxy-phenyl) -1,1-dimethyl-ethylamino] -1-hydroxy-ethyl} -6-hydroxy-4H-benzo [1,4] oxazin-3 -one
    [0081] 4- (4- {2- [2-hydroxy-2- (6-hydroxy-3-oxo-3,4-dihydro-2H-benzo [1,4] oxazin-8-yl) -ethylamino acid ] -2-methyl-propyl} -phenoxy) -butyric
    [0082] 8- {2- [2- (3.4-difluoro-phenyl) -1,1-dimethyl-ethylamino] -1-hydroxy-ethyl} -6-hydroxy-4H-benzo [1,4] oxazin-3 -one
    [0083] 1- (4-ethoxy-carbonylamino-3-cyano-5-fluorophenyl) -2- (tert-butylamino) ethanol
    [0084] 2-hydroxy-5- (1-hydroxy-2- {2- [4- (2-hydroxy-2-phenyl-ethylamino) -phenyl] -ethylamino} -ethyl) -benzaldehyde
    [0085] N- [2-hydroxy-5- (1-hydroxy-2- {2- [4- (2-hydroxy-2-phenyl-ethylamino) -phenyl] -ethylamino} -ethyl) -phenyl] -formamide
    [0086] 8-hydroxy-5- (1-hydroxy-2- {2- [4- (6-methoxy-biphenyl-3-ylamino) -phenyl] -ethylamino} -ethyl) -1H-quinolin-2-one
    [0087] 8-hydroxy-5- [1-hydroxy-2- (6-phenethylaminohexylamino) -ethyl] -1H-quinolin-2-one
    [0088] 5- [2- (2- {4- [4- (2-amino-2-methyl-propoxy) -phenylamino] -phenyl} -ethylamino) -1-hydroxy-ethyl] -8-hydroxy-1H -quinolin-2-one
    [0089] [3- (4- {6- [2-hydroxy-2- (4-hydroxy-3-hydroxymethyl-phenyl) -ethylamino] -hexyloxy} -butyl) -5-methyl-phenyl] -urea
    [0090] 4- (2- {6- [2- (2,6-dichloro-benzyloxy) -ethoxy] -hexylamino} -1- hydroxy-ethyl) -2-hydroxymethyl-phenol
    [0091] 3- (4- {6- [2-hydroxy-2- (4-hydroxy-3-hydroxymethyl-phenyl) -ethylamino] -hexyloxy} -butyl) -benzylsulfonamide
    [0092] 3- (3- {7- [2-hydroxy-2- (4-hydroxy-3-hydroxymethyl-phenyl) -ethylamino] -heptyloxy} -propyl) -benzylsulfonamide
    [0093] 4- (2- {6- [4- (3-cyclopentanesulfonyl-phenyl) -butoxy] -hexylamino} -1-hydroxy-ethyl) -2-hydroxymethyl-phenol
    [0094] N-adamantan-2-yl-2- (3- {2- [2-hydroxy-2- (4-hydroxy-3-hydroxymethyl-phenyl) -ethylamino] -propyl} -phenyl) -acetamide
    [0095] Optionally in the form of racemates, enantiomers, di-astereomers thereof and optionally in the form of pharmacologically acceptable acid addition salts, solvates or hydrates thereof. According to the invention, the acid addition salts of betamimetics are preferably selected from the hydrochloride, hydrobromide, iodhydrate, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartarate, hydroxy hydrate, hydroxy hydrate, hydroxide and hydro-p-toluenesulfonate.
    [0096] The anticholinergics used are preferably compounds selected from the tiotropium salts, preferably the bromide salt, oxytropium salts, preferably the bromide salt, fluoropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt, tropium salts, preferably the chloride salt, tolterodine. In the aforementioned salts, cations are the pharmacologically active constituents. As anions, the aforementioned salts may preferably contain chloride, bromide, iodide, sulfate, phosphate, methanesulfone, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulfonate, although chloride , bromide, iodide, sulfate, methanesulfonate or p-toluenesulfonate are preferred as counterions. Of all salts, chlorides, bromides, iodides and methanesulfonates are particularly preferred.
    [0097] Other preferred anticholinergics are selected from the salts of the formula AC-1

    [0098] wherein X- denotes an anion with a simple negative charge, preferably an anion selected from fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate , succinate, benzoate and p-toluenesulfonate, preferably an anion with a simple negative charge, particularly preferably an anion selected from fluoride, chloride, bromide, methanesulfonate and p-toluenesulfonate, particularly preferably bromide, optionally in the form of the racemates, enantiomers or hydrates thereof. Of particular importance are those pharmaceutical combinations containing the enantiomers of the formula AC-1-ene AC-1-ene

    [0099] where X- can have the aforementioned meanings. Other preferred anticholinergics are selected from the salts of the formula AC-2

    [00100] where R denotes methyl or ethyl and where X- can have the aforementioned meanings. In an alternative embodiment, the compound of the formula AC-2 can also be present in the form of the free base AC-2-base.

    [00101] Other specified compounds are:
    [00102] tropenol 2,2-diphenylpropionate metobromide
    [00103] scopin 2,2-diphenylpropionate metobromide
    [00104] scopin 2-fluoro-2,2-diphenylacetate metobromide
    [00105] tropenol 2-fluoro-2,2-diphenylacetate metobromide
    [00106] 3,3 ', 4,4’-tetrafluorobenzylate tropenol metobromide
    [00107] 3,3 ', 4,4’-scopin tetrafluorobenzylate metobromide
    [00108] tropenol 4,4'-difluorobenzylate metobromide
    [00109] scopin 4,4'-difluorobenzylate metobromide
    [00110] tropenol 3,3'-difluorobenzylate metobromide
    [00111] scopin 3,3'-difluorobenzylate metobromide
    [00112] tropenol 9-hydroxy-fluorene-9-carboxylate metobromide
    [00113] tropenol 9-fluoro-fluorene-9-carboxylate metobromide
    [00114] scorpion 9-hydroxy-fluorene-9-carboxylate metobromide
    [00115] scopin 9-fluoro-fluorene-9-carboxylate metobromide
    [00116] tropenol 9-methyl-fluorene-9-carboxylate metobromide
    [00117] scopin 9-methyl-fluorene-9-carboxylate metobromide
    [00118] cyclopropyltropin benzylate metobromide;
    [00119] cyclopropyltropin 2,2-diphenylpropionate metobromide
    [00120] cyclopropyltropin 9-hydroxy-xanthene-9-carboxylate metobromide
    [00121] cyclopropyltropin 9-methyl-fluorene-9-carboxylate metobromide
    [00122] cyclopropyltropin 9-methyl-xanthene-9-carboxylate metobromide
    [00123] cyclopropyl propyl 9-hydroxy-fluorene-9-carboxylate metobromide
    [00124] cyclopropyltropin methyl 4,4'-difluorobenzylate metobromide
    [00125] tropenol 9-hydroxy-xanthene-9-carboxylate metobromide
    [00126] scopine 9-hydroxy-xanthene-9-carboxylate metobromide
    [00127] tropenol 9-methyl-xanthene-9-carboxylate metobromide
    [00128] scopin 9-methyl-xanthene-9-carboxylate metobromide
    [00129] tropenol 9-ethyl-xanthene-9-carboxylate metobromide
    [00130] tropenol 9-difluoromethyl-xanthene-9-carboxylate metobromide
    [00131] scopin 9-hydroxymethyl-xanthene-9-carboxylate metobromide
    [00132] The aforementioned compounds can also be used as salts within the scope of the present invention, where instead of the metobromide the metho-X salts are used, where X can have the meanings given previously for X-.
    [00133] As corticosteroids it is preferable to use compounds selected from beclomethasone, betamethasone, budesonide, butoxocort, ciclesonide, deflazacort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rnisone, rnisone, rnisone, rnisone, rnisone 106541, NS-126, ST-26 and
    [00134] (S) -fluoromethyl 6,9-difluoro-17 - [(2-furanylcarbonyl) oxy] -11-hydroxy-16-methyl-3-oxo-androsta-1,4-diene-17-carbothionate
    [00135] (S) - (2-oxo-tetrahydro-furan-3S-yl) 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-propionyloxy-androsta-1,4-diene- 17-carbothionate,
    [00136] 6α, 9α-difluoro-11 β-hydr0xi-16α-methyl-3-oxo-17α- (2,2,3,3-tertamethylcyclopropylcarbonyl) 0xi-androsta-1,4-diene-17β-cyanomethyl carboxylate
    [00137] Optionally in the form of racemates, enantiomers or diastereomers thereof and optionally in the form of salts and derivatives thereof, solvates and / or hydrates thereof. Any reference to steroids includes a reference to any salts or derivatives, hydrates or solvates thereof that may exist. Examples of possible steroid salts and derivatives can be: alkali metal salts, such as, for example, sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen phosphate, palmitates, pivalates or furoates.
    [00138] PDE4 inhibitors that can be used are preferably compounds selected from enprofilina, theophylline, roflumilast, ariflo (cilomilast), tofimilast, pumafentrina, lirimilast, arophylline, atizoram, D-4418, Bay-198004, BY343, CP-325.366 D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V-11294A, Cl- 1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370 and
    [00139] N- (3,5-dichloro-1-oxo-pyridin-4-yl) -4-difluoromethoxy-3-cyclopropylmethoxybenzamide
    [00140] (-) p - [(4aR *, 10bS *) - 9-ethoxy-1,2,3,4,4a, 10b-hexahydro-8-methoxy-2-methylbenzo [s] [1.6] naphthyridin-6-yl] -N, N-di-hisopropylbenzamide
    [00141] (R) - (+) - 1- (4-bromobenzyl) -4 - [(3-cyclopentyloxy) -4-methoxyphenyl] -2-pyrrolidone
    [00142] 3- (cyclopentyloxy-4-methoxyphenyl) -1- (4-N '- [N-2-cyano-S-methyl-isothioureide] benzyl) -2-pyrrolidone
    [00143] cis [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1-carboxylic acid]
    [00144] 2-carbomethoxy-4-cyano-4- (3-cyclopropylmethoxy-4-difluoromethoxy-phenyl) cyclohexan-1-one
    [00145] cis [4-cyano-4- (3-cyclopropylmethoxy-4-difluoromethoxyphenyl) cyclohexan-1-ol]
    [00146] (R) - (+) - ethyl [4- (3-cyclopentyloxy-4-methoxyphenyl) pyrrolidin-2-ylidene] acetate
    [00147] (S) - (-) - ethyl [4- (3-cyclopentyloxy-4-methoxyphenyl) pyrrolidin-2-ylidene] acetate
    [00148] 9-cyclopentyl-5,6-dihydro-7-ethyl-3- (2-thienyl) -9H-pyrazolo [3,4-c] - 1,2,4-triazolo [4,3-a] pyridine
    [00149] 9-cyclopentyl-5,6-dihydro-7-ethyl-3- (tert-butyl) -9H-pyrazolo [3,4-c] -1,2,4-triazolo [4,3-a] pyridine
    [00150] Optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts thereof, the solves and / or hydrates thereof. According to the invention, the acid addition salts of the PDE4 inhibitors are preferably selected from the hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydroxide, hydroxide , hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
    [00151] The LTD4 antagonists used are preferably compounds selected from montelukast, pranlukast, zafirlukast, NCC-847 (ZD-3523), MN-001, MAN-91507 (LM-1507), VUF-5078, VUF-K- 8707 , L-733321 and
    [00152] 1 - ((((R) - (3- (2- (6,7-difluoro-2-quinolinyl) ethenyl) phenyl) -3- (2- (2-hydroxy-2-propyl) phenyl) acid uncle) methylcyclopropane-acetic,
    [00153] acid 1 - (((1 (R) -3 (3- (2- (2,3-dichlorothieno [3,2-b] pyridin-5-iI) - (E) -ethyl) phenyl) - 3- (2- (1-hydroxy-1-methylethyl) phenyl) propyl) thio) methyl) cyclopropanoacetic
    [00154] [2 - [[2- (4-tert-butyl-2-thiazolyl) -5-benzo-furanyl] oximeyl] phenyl] acetic acid
    [00155] Optionally in the form of racemates, enantiomers or diastereomers thereof and optionally in the form of pharmacologically acceptable acid addition salts, solvates and / or hydrates thereof. According to the invention, these acid addition salts are preferably selected from the hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotreat, hydroxalate, hydroxide and hydroxycuccinate. hydro-p-toluenesulfonate. By salts or derivatives that LTD4 antagonists may optionally be able to form are meant, for example: alkali metal salts, such as, for example, sodium or potassium salts, alkaline earth metal salts, sulfobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates.
    [00156] EGFR inhibitors that can be used are preferably compounds selected from cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and
    [00157] 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -7-cyclopropylmethoxy -quinazoline
    [00158] 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-diethylamino) -1- oxo-2-buten-1-yl] amino} -7-cyclopropylmethoxy -quinazoline
    [00159] 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -1- oxo-2-buten-1-yl] amino} -7-cyclopropylmethoxy -quinazoline
    [00160] 4 - [(R) - (1-phenyl-ethyl) amino] -6 - {[4- (morpholin-4-yl) -1-oxo-2-buten- 1-yl] amino} -7 -cyclopentyloxy-quinazoline
    [00161] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6 - {[4 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -1-oxo- 2-buten-1-yl] amino} -7-cyclopropylmethoxy-quinazoline
    [00162] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6 - {[4 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -1-oxo- 2-buten-1-yl] amino} -7 - [(S) - (tetrahydrofuran-3-yl) oxy] - quinazoline
    [00163] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6 - {[4 - ((R) -2-methoxymethyl-6-oxo-morpholin-4-yl) -1-oxo- 2-buten-1-yl] amino} -7-cyclopropylmethoxy-quinazoline
    [00164] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [2 - ((S) -6-methyl-2-oxo-morpholin-4-yl) -ethoxy] -7- methoxy-quinazoline
    [00165] 4 - [(3-chloro-4-fluorophenyl) amino] -6 - ({4- [N- (2-methoxy-ethyl) -N-methyl-amino] -1-oxo-2-buten- 1-yl} amino) -7-cyclopropylmethoxy-quinazoline
    [00166] 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -1- oxo-2-buten-1-yl] amino} -7-cyclopentyloxy -quinazoline
    [00167] 4 - [(R) - (1-phenyl-ethyl) amino] -6 - {[4- (N, N-para- (2-methoxy-ethyl) - amino) -1-oxo-2- buten-1-yl] amino} -7-cyclopropylmethoxy-quinazoline
    [00168] 4 - [(R) - (1-phenyl-ethyl) amino] -6 - ({4- [N- (2-methoxy-ethyl) -N-ethyl-amino] -1-oxo-2- buten-1-yl} amino) -7-cyclopropylmethoxy-quinazoline
    [00169] 4 - [(R) - (1-phenyl-ethyl) amino] -6 - ({4- [N- (2-methoxy-ethyl) -N-methyl-amino] -1-oxo-2- buten-1-yl} amino) -7-cyclopropylmethoxy-quinazoline
    [00170] 4 - [(R) - (1-phenyl-ethyl) amino] -6 - ({4- [N- (tetrahydropyran-4-yl) -N-methyl-amino] -1-oxo-2- buten-1-yl} amino) -7-cyclopropylmethoxy-quinazoline
    [00171] 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -1- oxo-2-buten-1-yl] amino} -7- ( (R) -tetrahydrofuran-3-yloxy) -quinazoline
    [00172] 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -1- oxo-2-buten-1-yl] amino} -7- ( (S) -tetrahydrofuran-3-yloxy) -quinazoline
    [00173] 4 - [(3-chloro-4-fluorophenyl) amino] -6 - ({4- [N- (2-methoxy-ethyl) -N-methyl-amino] -1-oxo-2-buten- 1-yl} amino) -7-cyclopentyloxy-quinazoline
    [00174] 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N-cyclopropyl-N-methyl-amino) -1-oxo-2-buten-1-yl] amino} -7-cyclopentyloxy-quinazoline
    [00175] 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -1- oxo-2-buten-1-yl] amino} -7- [ (R) - (tetrahydrofuran-2-yl) methoxy] -quinazoline
    [00176] 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -1- oxo-2-buten-1-yl] amino} -7- [ (S) - (tetrahydrofuran-2-yl) methoxy] -quinazoline
    [00177] 4 - [(3-ethynyl-phenyl) amino] -6.7-para- (2-methoxy-ethoxy) - quinazoline
    [00178] 4 - [(3-chloro-4-fluorophenyl) amino] -7- [3- (morpholin-4-yl) -propyloxy] - 6 - [(vinylcarbonyl) amino] -quinazoline
    [00179] 4 - [(R) - (1-phenyl-ethyl) amino] -6- (4-hydroxy-phenyl) -7H-pyrrolo [2,3- d] pyrimidine
    [00180] 3-cyano-4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (N, N-dimethylamino) -1-oxo-2-buten-1-yl] amino} -7-ethoxy-quinoline
    [00181] 4 - {[3-chloro-4- (3-fluoro-benzyloxy) -phenyl] amino} -6- (5 - {[(2-methanesulfonyl-ethyl) amino] methyl} -furan-2-yl ) quinazoline
    [00182] 4 - [(R) - (1-phenyl-ethyl) amino] -6 - {[4 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -1-oxo- 2-buten-1-yl] amino} -7-methoxy-quinazoline
    [00183] 4 - [(3-chloro-4-fluorophenyl) amino] -6 - {[4- (morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -7- [ (tetrahydrofuran-2-yl) methoxy] -quinazoline
    [00184] 4 - [(3-chloro-4-fluorophenyl) amino] -6 - ({4- [N, N-para- (2-methoxy-ethyl) -amino] -1-oxo-2-buten- 1-yl} amino) -7 - [(tetrahydrofuran-2-yl) methoxy] - quinazoline
    [00185] 4 - [(3-ethynyl-phenyl) amino] -6 - {[4- (5.5-dimethyl-2-oxo-morpholin-4-yl) -1-oxo-2-buten-1-yl] amino} -quinazoline
    [00186] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] -7-methoxy- quinazoline
    [00187] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] -7 - [( R) - (tetrahydrofuran-2-yl) methoxy] -quinazoline
    [00188] 4 - [(3-chloro-4-fluoro-phenyl) amino] -7- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] -6 - [( S) - (tetrahydrofuran-2-yl) methoxy] -quinazoline
    [00189] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {2- [4- (2-oxo-morpholin-4-yl) -piperidin-1-yl] -ethoxy} - 7-methoxy-quinazoline
    [00190] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [1- (tert-butyloxycarbonyl) - piperidin-4-yloxy] -7-methoxy-quinazoline
    [00191] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (trans-4-amino-cyclohexan-1-yloxy) -7-methoxy-quinazoline
    [00192] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (trans-4-methanesulfonylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline
    [00193] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (tetrahydropyran-3-yloxy) -7-methoxy-quinazoline
    [00194] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-methyl-piperidin-4-yloxy) - 7-methoxy-quinazoline
    [00195] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {1 - [(morpholin-4-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline
    [00196] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {1 - [(methoxymethyl) carbonyl] - piperidin-4-yloxy} -7-methoxy-quinazoline
    [00197] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (piperidin-3-yloxy) -7- methoxy-quinazoline
    [00198] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [1- (2-acetylamino-ethyl) - piperidin-4-yloxy] -7-methoxy-quinazoline
    [00199] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (tetrahydropyran-4-yloxy) -7- ethoxy-quinazoline
    [00200] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6 - ((S) -tetrahydrofuran-3-yloxy) -7-hydroxy-quinazoline
    [00201] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (tetrahydropyran-4-yloxy) -7- (2-methoxy-ethoxy) -quinazoline
    [00202] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {trans-4- [(dimethylamino) sulfonylamino] -cyclohexan-1-yloxy} -7-methoxy-quinazoline
    [00203] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {trans-4 - [(morpholin-4-yl) carbonylamino] -cyclohexan-1-yloxy} -7-methoxy-quinazoline
    [00204] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {trans-4 - [(morpholin-4-yl) sulfonylamino] -cyclohexan-1-yloxy} -7-methoxy-quinazoline
    [00205] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (tetrahydropyran-4-yloxy) -7- (2-acetylamino-ethoxy) -quinazoline
    [00206] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (tetrahydropyran-4-yloxy) -7- (2-methanesulfonylamino-ethoxy) -quinazoline
    [00207] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {1 - [(piperidin-1-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline
    [00208] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-aminocarbonylmethyl-piperidin-4-yloxy) -7-methoxy-quinazoline
    [00209] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (cis-4- {N - [(tetrahydropyran-4-yl) carbonyl] -N-methyl-amino} -cycloexan- 1-yloxy) -7-methoxy-quinazoline
    [00210] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (cis-4- {N - [(morpholin-4-yl) carbonyl] -N-methyl-amino} -cyclohexan- 1-yloxy) -7-methoxy-quinazoline
    [00211] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (cis-4- {N - [(morpholin-4-yl) sulfonyl] -N-methyl-amino} -cyclohexan- 1-yloxy) -7-methoxy-quinazoline
    [00212] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (trans-4-ethanesulfonylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline
    [00213] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7-ethoxy-quinazoline
    [00214] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7- (2-methoxy-ethoxy) -quinazoline
    [00215] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [1- (2-methoxy-acetyl) - piperidin-4-yloxy] -7- (2-methoxy-ethoxy) - quinazoline
    [00216] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (cis-4-acetylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline
    [00217] 4 - [(3-ethynyl-phenyl) amino] -6- [1- (tert-butyloxycarbonyl) -piperidin-4-yloxy] -7-methoxy-quinazoline
    [00218] 4 - [(3-ethynyl-phenyl) amino] -6- (tetrahydropyran-4-yloxy] -7-methoxy-quinazoline
    [00219] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (cis-4- {N - [(piperidin-1-yl) carbonyl] -N-methyl-amino} -cyclohexan- 1-yloxy) -7-methoxy-quinazoline
    [00220] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (cis-4- {N - [(4-methyl-piperazin-1-yl) carbonyl] -N-methyl-amino } -cyclohexan-1-yloxy) -7-methoxy-quinazoline
    [00221] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {cis-4 - [(morpholin-4-yl) carbonylamino] -cyclohexan-1-yloxy} -7-methoxy-quinazoline
    [00222] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {1- [2- (2-oxopyrrolidin-1-yl) ethyl] -piperidin-4-yloxy} -7-methoxy -quinazoline
    [00223] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {1 - [(morpholin-4-yl) carbonyl] -piperidin-4-yloxy} -7- (2-methoxy- ethoxy) -quinazoline
    [00224] 4 - [(3-ethynyl-phenyl) amino] -6- (1-acetyl-piperidin-4-yloxy) -7-methoxy-quinazoline
    [00225] 4 - [(3-ethynyl-phenyl) amino] -6- (1-methyl-piperidin-4-yloxy) -7-methoxy-quinazoline
    [00226] 4 - [(3-ethynyl-phenyl) amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7-methoxy-quinazoline
    [00227] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-methyl-piperidin-4-yloxy) - 7 (2-methoxy-ethoxy) -quinazoline
    [00228] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-isopropyloxycarbonyl-piperidin-4-yloxy) -7-methoxy-quinazoline
    [00229] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (cis-4-methylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline
    [00230] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {cis-4- [N- (2-methoxy-acetyl) -N-methyl-amino] -cyclohexan-1-yloxy } -7-methoxy-quinazoline
    [00231] 4 - [(3-ethynyl-phenyl) amino] -6- (piperidin-4-yloxy) -7-methoxy-quinazoline
    [00232] 4 - [(3-ethynyl-phenyl) amino] -6- [1- (2-methoxy-acetyl) -piperidin-4-yloxy] -7-methoxy-quinazoline
    [00233] 4 - [(3-ethynyl-phenyl) amino] -6- {1 - [(morpholin-4-yl) carbonyl] - piperidin-4-yloxy} -7-methoxy-quinazoline
    [00234] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {1 - [(cis-2,6-dimethyl-morpholin-4-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline
    [00235] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {1 - [(2-methyl-morpholin-4-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy -quinazoline
    [00236] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {1 - [(S, S) - (2-oxa-5-aza-bicyclo [2,2,1] hept -5-yl) carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline
    [00237] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {1 - [(N-methyl-N-2-methoxyethyl-amino) carbonyl] -piperidin-4-yloxy} -7 -methoxy-quinazoline
    [00238] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-ethyl-piperidin-4-yloxy) -7-methoxy-quinazoline
    [00239] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {1 - [(2-methoxyethyl) carbonyl] - piperidin-4-yloxy} -7-methoxy-quinazoline
    [00240] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- {1 - [(3-methoxypropyl-amino) -carbonyl] -piperidin-4-yloxy} -7-methoxy-quinazoline
    [00241] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [cis-4- (N-methanesulfonyl- N-methyl-amino) -cyclohexan-1-yloxy] -7-methoxy- quinazoline
    [00242] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [cis-4- (N-acetyl-N-methyl-amino) -cyclohexan-1-yloxy] -7-methoxy- quinazoline
    [00243] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (trans-4-methylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline
    [00244] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [trans-4- (N-methanesulfonyl-N-methyl-amino) -cyclohexan-1-yloxy] -7-methoxy quinazoline
    [00245] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (trans-4-dimethylamino-cyclohexan-1-yloxy) -7-methoxy-quinazoline
    [00246] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (trans-4- {N - [(morpholin-4-yl) carbonyl] -N-methyl-amino} -cyclohexan- 1-yloxy) -7-methoxy-quinazoline
    [00247] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- [2- (2,2-dimethyl-6-oxo-morpholin-4-yl) -ethoxy] -7 - [( S) - (tetrahydrofuran-2-yl) methoxy] -quinazoline
    [00248] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-methanesulfonyl-piperidin-4-yloxy) -7-methoxy-quinazoline
    [00249] 4 - [(3-chloro-4-fluoro-phenyl) amino] -6- (1-cyano-piperidin-4-yloxy) - 7-methoxy-quinazoline
    [00250] Optionally in the form of racemates, enantiomers, di-astereomers thereof and optionally in the form of pharmacologically acceptable acid addition salts, solvates or hydrates thereof. According to the invention, these acid addition salts are preferably selected from the hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrocartrate, hydroxate, hydroxate , hydrobenzoate and hydro-p-toluenesulfonate.
    [00251] The dopamine agonists used are preferably compounds selected from bromocriptine, cabergoline, alpha-dihydroergocriptine, lisuride, pergolide, pramipexole, roxindol, ropinirole, talipexole, tergurid and viozan, optionally in the form of racemates, enantiomers and, optionally, diastereomers and the same diastereomers and optional diastereomers in the form of pharmacologically acceptable acid addition salts, solvates or hydrates thereof. According to the invention, these acid addition salts are preferably selected from the hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofum-rat, hydrocartrate, hydrooxalate, hydro-succinate and hydro-p-toluenesulfonate.
    [00252] H1-antihistamines that can be used are preferably compounds selected from epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimethindene, clemastine, bamyramine, phenylamine, camine chlorophenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine and meclozine, optionally in the form of racemates, enantiomers, diastereomers thereof and optionally in the form of pharmacologically acceptable acid addition salts, solvates or hydrates thereof. According to the invention, these acid addition salts are preferably selected from the hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydroxalate, hydroxalate , hydrobenzoate and hydro-p-toluenesulfonate.
    [00253] The pharmaceutically effective substances, formulations or mixtures of substances used can be any inhalable compound, including also for example, inhalable macromolecules, as disclosed in EP 1 003 478. Preferably, the substances, formulations or mixtures of substances to treat respiratory complications that are administered by inhalation are used.
    [00254] Furthermore, the compound may come from the group of ergot alkali derivatives, triptans, CGRP inhibitors, phosphodiesterase V inhibitors, optionally in the form of racemates, enantiomers or diastereomers thereof, optionally in the form of salts addition of pharmacologically acceptable acids, the solvates and / or hydrates thereof.
    [00255] Examples of derivatives of ergot alkaloids are dihydroergotamine and ergotamine. List of reference numerals: 1. cover 2. nozzle 2 ’. opening aid 3. plate 4. spindle 5. capsule retainer 6. bottom 6 ’. inspection window 7. external actuating member 8. pin 9. helical spring 10. internal actuating member 11. pin 12. mesh housing 13. mesh mesh 14. closing element 15. guide arm 16. recess 17. retaining nets 18. retainer 19. opening of 6 20. guide pin 20 '. guide sleeve 21. capsule chamber 21 ’. capsule 22. replaceable tube 23. plug 24. opening 22 25. top 22 22. insertion cone 27. opening 2 28. ear 29. groove 30. annular groove 31. depression 32. slope 23 23. hook 37 hitch 34. intermediate ring 35. compression spring 36. retainer ring 37. actuator button 38. 34 neck 34. bar 40. axial bore 41. cross member 42. recess 43. 23 hook hitch 44. opening 3 45. nozzle
    权利要求:
    Claims (14)
    [0001]
    1. Inhaler for inhaling powdered medicine capsules, comprising: - a lower part (6), - a plate (3) accommodated in the lower part (6), and a retainer (18) inserted in the lower part (6), - a nozzle (2) that can be engaged to the bottom (6) on the plate (3), - a cover (1) covering the nozzle (2) in a closed position, and - an actuating member (7, 10) that it can be moved from a rest position and in one movement and at the same time it cooperates with at least one pin (8, 11) that can be inserted in the retainer (18) and is located in a pin retainer of the internal actuating member (10 ), characterized by the fact that, as an expulsion channel, a replaceable tube (22) can be inserted in the retainer (18), and the replaceable tube (22) - has a capsule chamber (21) with the capsule and - it is releasably attached to the inhaler in its position of use and extends through the mouthpiece (2).
    [0002]
    Inhaler according to claim 1, characterized in that the replaceable tube (22) with the capsule can be used for a single inhalation.
    [0003]
    Inhaler according to claim 1 or 2, characterized by the fact that the replaceable tube (22) is actively released by operating an actuator button (37).
    [0004]
    4. Inhaler according to claim 3, characterized by the fact that the actuator button (37) is on the side of the inhaler opposite the nozzle (2) and the replaceable tube (22) is released by pressing the actuator button (37).
    [0005]
    Inhaler according to any one of claims 1 to 4, characterized in that the inhaler has a locking device for retaining the replaceable tube (22) in its axial position of use, the locking device comprising at least an engagement hook (43) that engages an associated recess (31).
    [0006]
    6. Inhaler according to claim 5, characterized by the fact that a radial bar (39) is formed in a resiliently mounted intermediate ring (34), said bar (39) cooperating with the actuating member (7, 10) of so that, when no replaceable tube (22) is present, or no replaceable tube (22) is attached in the axial position of use, it secures the actuating member (7, 10) to prevent it from moving to pierce the capsule , and when a replaceable tube (22) is attached in the axial position of use, the bar (39) releases the actuating member (7, 10) to pierce the capsule with the pins.
    [0007]
    7. Inhaler according to claim 6, characterized by the fact that the intermediate ring (34) is guided in an axially removable way, by means of an interposed compression spring (35), in a retaining ring (36) attached to its base at the bottom (6).
    [0008]
    8. Inhaler according to claim 6 or 7, characterized in that the intermediate ring (34) has a coaxial actuator button (37) that protrudes through the retaining ring (36) and an opening (19) at the bottom which is more particularly bivalve, for actuation by a user to release the coupling.
    [0009]
    9. Inhaler according to any one of claims 5 to 8, characterized in that the coupling hook (43) acts radially and retains the replaceable tube (22) reliably in the inhaler by means of a coupling, the replaceable tube (22) having for this purpose a depression (31), particularly together with longitudinal and annular grooves (30) to which the hook (43) is attached.
    [0010]
    Inhaler according to any one of claims 1 to 9, characterized in that the replaceable tube (22) is movably engaged in an inserted intermediate position that it occupies between the use position and its removal.
    [0011]
    Inhaler according to any one of claims 1 to 10, characterized in that the capsule chamber (21) is of suitable size and shape to receive a plurality of capsules that can be pierced by means of corresponding pins (8, 11).
    [0012]
    Inhaler according to any one of claims 1 to 11, characterized in that the external actuating member (7) is blocked to prevent it from being tightened if the replaceable tube (22) is not inserted correctly.
    [0013]
    13. Inhaler according to any one of claims 1 to 12, characterized by the fact that the replaceable tube (22) has, on its circumferential side, openings (24) for the pins (8, 11), the openings ( 24) are closed by a membrane.
    [0014]
    14. Replaceable tube (22), characterized by the fact that it is configured to be inserted into the inhaler as defined in claim 1.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112012007303B1|2020-12-15|INHALER FOR INHALING DRUGS IN CAPSULE POWDER AND INSERTIBLE TUBE
    JP6048767B2|2016-12-21|Adapter, inhaler and atomizer
    US7870856B2|2011-01-18|Inhaler
    JP5194324B2|2013-05-08|Inhaler
    JP4995324B2|2012-08-08|Powder inhaler
    JP4954273B2|2012-06-13|Inhaler
    US8397717B2|2013-03-19|Inhaler with mouthpiece having a microbiological protective function
    US8919342B2|2014-12-30|Inhaler
    US9604017B2|2017-03-28|Needle for piercing a powder capsule for inhalation
    JP5233049B2|2013-07-10|Inhaler mouthpiece
    同族专利:
    公开号 | 公开日
    CN102573972B|2014-12-03|
    BR112012007303A2|2016-04-19|
    EP2482904A2|2012-08-08|
    EA201200374A1|2013-05-30|
    ES2622839T3|2017-07-07|
    JP2015128654A|2015-07-16|
    AR078514A1|2011-11-16|
    EA023920B1|2016-07-29|
    KR101719137B1|2017-03-23|
    NZ599305A|2014-06-27|
    KR20120084302A|2012-07-27|
    US8746244B2|2014-06-10|
    JP2013506472A|2013-02-28|
    AU2010302695A1|2012-05-03|
    WO2011039307A3|2011-06-16|
    US20110232637A1|2011-09-29|
    WO2011039307A4|2011-07-28|
    CN102573972A|2012-07-11|
    WO2011039307A2|2011-04-07|
    CL2012000817A1|2012-08-03|
    CA2776286A1|2011-04-07|
    AU2010302695B2|2015-04-02|
    JP6160642B2|2017-07-12|
    TWI571277B|2017-02-21|
    JP5744883B2|2015-07-08|
    BR112012007303B8|2021-06-22|
    EP2482904B1|2017-03-15|
    CA2776286C|2016-12-06|
    IL218545D0|2012-05-31|
    IL218545A|2015-09-24|
    CN104307075B|2017-04-26|
    CN104307075A|2015-01-28|
    TW201134508A|2011-10-16|
    DK2482904T3|2017-07-03|
    ZA201201731B|2013-01-30|
    MX2012003444A|2012-04-20|
    EP3189869A1|2017-07-12|
    EP3189869B1|2019-07-03|
    HUE034526T2|2018-02-28|
    PL2482904T3|2017-09-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US2946332A|1957-12-23|1960-07-26|Nysco Lab Inc|Insufflator|
    FR2352556B1|1976-05-26|1980-04-11|Pasteur Institut|
    IT1116047B|1979-04-27|1986-02-10|Sigma Tau Ind Farmaceuti|DEVICE FOR THE QUICK INHALATION OF POWDER DRUGS BY PERSONS SUFFERING FROM ASTHMA|
    DE3927170A1|1989-08-17|1991-02-21|Boehringer Ingelheim Kg|INHALATOR|
    DE4318455A1|1993-06-03|1994-12-08|Boehringer Ingelheim Kg|Capsule holder|
    JP3372105B2|1994-05-26|2003-01-27|株式会社日立ユニシアオートモティブ|Inhalation type dispenser|
    DE19733651A1|1997-08-04|1999-02-18|Boehringer Ingelheim Pharma|Aqueous aerosol preparations containing biologically active marrow molecules and processes for producing corresponding aerosols|
    DE19835346A1|1998-08-05|2000-02-10|Boehringer Ingelheim Pharma|Two-part capsule for pharmaceutical preparations for powder inhalers|
    JP4332502B2|2002-09-16|2009-09-16|ジークフリート・ジェネリクス・インターナショナル・アクチェンゲゼルシャフト|Inhaler for powdered substances|
    DE10352277A1|2003-11-08|2005-06-02|Boehringer Ingelheim Pharma Gmbh & Co. Kg|powder inhaler|
    GB0420513D0|2004-09-15|2004-10-20|Optinose As|Powder delivery devices|
    EP1827541B1|2004-10-21|2013-05-29|Boehringer Ingelheim International GmbH|Blister for inhalers|
    DE102006016904A1|2006-04-11|2007-10-25|Boehringer Ingelheim Pharma Gmbh & Co. Kg|inhaler|
    GB0623732D0|2006-11-28|2007-01-10|Optinose As|Powder delivery devices|
    DE102007036411A1|2007-07-20|2009-02-12|Boehringer Ingelheim Pharma Gmbh & Co. Kg|powder inhaler|
    US8746244B2|2009-10-02|2014-06-10|Boehringer Ingelheim International Gmbh|Powder inhaler|US6435686B1|1999-02-26|2002-08-20|The Ohtsu Tire & Rubber Co., Ltd.|Light conducting plate for a back lighting device and back lighting device|
    DE102007036411A1|2007-07-20|2009-02-12|Boehringer Ingelheim Pharma Gmbh & Co. Kg|powder inhaler|
    US8746244B2|2009-10-02|2014-06-10|Boehringer Ingelheim International Gmbh|Powder inhaler|
    US9345848B2|2009-10-20|2016-05-24|Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti.|Dry powder inhaler|
    GB201020638D0|2010-12-06|2011-01-19|Liconsa Laboratorios Sa|Inhalator|
    EA026450B1|2011-11-25|2017-04-28|Махмут Билджик|Inhalation device|
    DE102012103482A1|2012-04-20|2013-10-24|Alfred Von Schuckmann|Device for inhaling powdery substances|
    US9956362B2|2012-05-25|2018-05-01|Arven Ilac Saniyi ve Ticaret A.S.|Trigger mechanism for inhaler device|
    US9248247B2|2012-07-26|2016-02-02|Nathaniel Gerald Portney|Capsular medication delivery and inhalation device|
    AU356658S|2014-01-28|2014-07-29|Lupin Ltd|Inhaler|
    AU356644S|2014-01-28|2014-07-29|Lupin Ltd|Inhaler|
    AU356657S|2014-01-28|2014-07-29|Lupin Ltd|Inhaler|
    AU355712S|2014-02-20|2014-05-22|Lupin Ltd|Part of inhaler|
    NO2709641T3|2014-03-10|2018-05-12|
    DE102015109996B3|2015-06-22|2016-07-28|Gerresheimer Regensburg Gmbh|Device for opening capsules|
    CA169756S|2016-02-08|2017-09-01|Nicoventures Holdings Ltd|Electronic cigarette|
    EP3419707A1|2016-02-24|2019-01-02|Boehringer Ingelheim International GmbH|Inhaler|
    EP3419708B1|2016-02-24|2019-11-20|Boehringer Ingelheim International GmbH|Inhaler|
    GB201605105D0|2016-03-24|2016-05-11|Nicoventures Holdings Ltd|Vapour provision apparatus|
    GB201605101D0|2016-03-24|2016-05-11|Nicoventures Holdings Ltd|Electronic vapour provision system|
    GB201605100D0|2016-03-24|2016-05-11|Nicoventures Holdings Ltd|Vapour provision system|
    PL3284499T3|2016-08-15|2019-11-29|Tiefenbacher Alfred E Gmbh & Co Kg|Dry powder inhaler with reproducible flow resistance|
    WO2021079343A1|2019-10-25|2021-04-29|Philip Morris Products S.A.|Inhaler article with open distal end, and inhaler system|
    法律状态:
    2019-01-08| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2019-07-09| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|
    2020-02-18| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|
    2020-07-21| B07G| Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]|
    2020-09-15| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2020-12-15| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
    2021-06-22| B16C| Correction of notification of the grant [chapter 16.3 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/09/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |
    优先权:
    申请号 | 申请日 | 专利标题
    EP09172107|2009-10-02|
    EP09172107.6|2009-10-02|
    PCT/EP2010/064562|WO2011039307A2|2009-10-02|2010-09-30|Powder inhaler|
    [返回顶部]